with final diagnoses. Results: CNB showed a lower rate of AUS/FLUS diagnosis, higher rates of benign and follicular neoplasm or suspicious for a follicular neoplasm (FN/SFN) diagnoses (p ≤ 0.038), and marginally higher rates of malignant diagnosis than RFNA in the NA subcategory. CNB showed a higher rate of FN/SFN (p = 0.007) than RFNA in the FOA subcategory. CNB also demonstrated a higher rate of surgery decision than RFNA in both the NA subcategory (20.2 vs. 9.6%, p < 0.001) and FOA subcategory (20.8 vs. 5.6%, p = 0.007), and a higher rate of observation decision only in the NA subcategory (48.1 vs. 35.6%, p = 0.035). CNB demonstrated a higher diagnostic performance for malignancy overall in the nodules compared with RFNA. Conclusion: CNB may be more useful for management decisions than RFNA in both the NA and FOA subcategories, and has the potential to be a first-line alternative diagnostic tool in initially diagnosed AUS/FLUS nodules. 
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Introduction
The Bethesda System for Reporting Thyroid Cytopathology (BSRTC) recommends repeat fine-needle aspiration (RFNA) for thyroid nodules initially diagnosed as atypia/follicular lesion of undetermined significance (AUS/FLUS) [1, 2] . However, the role of RFNA for AUS/ FLUS nodules is controversial. First, RFNA also reproduce significant inconclusive results. The rate of repeated AUS/FLUS results by RFNA is estimated to approximately be up to 67% [3] [4] [5] [6] . Second, RFNA may not provide a straightforward management decision for a nodule diagnosed as benign by RFNA because the false negative rate of a benign diagnosis by RFNA in nodules initially diagnosed as AUS/FLUS may be higher than that in a single benign diagnosis [7, 8] . Thyroid nodules with AUS/FLUS diagnosis include various pathologies, and recent studies [4, [9] [10] [11] [12] [13] [14] [15] demonstrate that subcategory nodules showing nuclear atypia (NA) have a higher malignancy risk than other subcategory nodules showing architectural or other atypia, which might require a different management strategy. Although several recent studies [16] [17] [18] [19] [20] [21] [22] have suggested the potential utility of core needle biopsy (CNB) in the management of AUS/FLUS or indeterminate nodules, the role of CNB has not been established and its utility has been little investigated for each subcategory of AUS/FLUS nodules [22] . This study was performed to determine whether CNB is more useful for management decisions than RFNA at each nodule subcategory in patients with AUS/FLUS nodules initially diagnosed by a prior FNA.
Materials and Methods
The institutional review board approved this retrospective study, and the requirement to obtain informed consent was waived.
Study Population
From February 2010 to June 2013, 643 (9.7%) consecutive nodules were initially diagnosed as AUS/FLUS among 6,604 thyroid nodules of 5,159 patients who underwent FNA. A total of 158 thyroid nodules of 153 consecutive patients (103 women, 50 men; mean age 51.8 ± 12.3 years) were enrolled for this study among 643 nodules diagnosed as AUS/FLUS. The inclusion criteria for enrollment were as follows: (a) patients who underwent both RFNA and CNB after an initial diagnosis of AUS/FLUS nodules by a prior FNA, and (b) thyroid nodules being equal to or larger than 10 mm. The patients who did not undergo follow-up biopsy or underwent only one of either RFNA or CNB were excluded.
The final diagnoses of malignant tumor and neoplasm were determined by the pathological results from surgical resections. Final diagnoses of benign nodules were determined by: (a) the pathological results of surgical resections, (b) with benign results of FNA or CNB repeated at least twice, or (c) with an initial benign result of FNA or CNB and a significant decrease of nodule size at ultrasound (US) follow-up.
US-Guided FNA and CNB Procedures
The FNA and CNB procedures were performed under highresolution color-Doppler US guidance using a 10-to 12-MHz linear transducer (AplioXG, Toshiba, Otawarashi, Japan; iU22, Philips Medical Systems, Bothell, Wash., USA) and by two experienced radiologists (D.G.N. and H.S.) with 15 and 7 years of experience of thyroid US imaging and intervention, respectively. FNA was performed with a conventional method and at least two samplings were performed for each nodule [23] . CNB was performed using a disposable 18-gauge, single-or double-action spring-activated needle (approx. 1-or 2-cm excursion; TSK Acecut or Stericut, Create Medic, Yokohama, Japan) as described elsewhere [17] . The needle notch of CNB was positioned to cut a portion of normal parenchyma (about 2 mm in length) at the nodule margin if technically feasible ( fig. 1 ). After patients underwent biopsy, we immediately compressed the biopsy site and they were observed with self manual compression of the biopsy site for 20-30 min. We made an effort to obtain the qualified cytology and histology specimens at each FNA and CNB procedure.
Cytology and Histology Analysis
All FNA cytology specimens were interpreted according to 6 categories of the BSRTC [1] . Two endocrine pathologists (H.S.M. and H.L.) retrospectively subcategorized the AUS/FLUS category into 2 subcategories of NA (n = 104) and follicular lesions with other atypia (FOA; n = 54). The NA subcategory included nodules with NA such as the presence of occasional nuclear grooves and irregularity, enlarged nuclei with a pale chromatin pattern, and nuclear overlapping or crowding, but which were not enough to be considered suspicious for malignancy. The FOA subcategory included nodules with architectural atypia such as the presence of a prominent population of microfollicles or Hurthle cells in sparsely cellular aspirates with scant colloid, but not enough to be diagnosed as a follicular neoplasm or suspicious for a follicular neoplasm (FN/SFN), and also included other undetermined atypical follicular lesions that were not enough to be included in the NA subcategory. A thyroid nodule showing both nuclear and architectural atypia was included in the NA subcategory.
The diagnostic categories of CNB for thyroid nodules have not yet been standardized. For this study, CNB histology diagnoses were also categorized into the same 6 categories of the Bethesda system according to the histopathology result of CNB [17, 24] . Category I of CNB included the absence of any identifiable follicular thyroid tissue, the presence of only a normal thyroid gland, and tissue containing only a few follicular cells that were insufficient for diagnosis. Category III of CNB included nodules with some atypical cells, but which were not diagnostic of suspected malignancy or malignancy, and included cellular follicular nodules in which the distinction between a follicular neoplasm and a hypercellular hyperplastic nodule was not possible. Category IV included nodules with histology features favoring follicular neoplasm and nodule capsules. The finding of the immunohistochemistry study was not considered when determining the categories of the CNB histopathology results.
Data Analysis and Statistics
McNemar's test was used to compare each diagnostic result of RFNA and CNB in the overall and subcategories of the nodules, to compare the rate of management decision, and to compare the sensitivity and specificity for the diagnosis of thyroid malignancy between RFNA and CNB. The χ 2 test or Fisher's exact test was used to compare the diagnostic results of RFNA or CNB between the subcategories of NA and FOA nodules. We compared the diagnostic performance for malignancy between RFNA and CNB by receiver operating characteristic (ROC) analysis.
For the assessment of diagnostic values we used two criteria of RFNA or CNB for the diagnosis of malignancy. Criteria 1 indicated diagnostic results of malignancy (BSRTC category VI) and criteria 2 indicated diagnostic results of FN/SFN or suspicious for malignancy or malignancy (BSRTC category IV/V/VI). Statistical analysis was performed with the SPSS software package (version 18.0 for Windows; SPSS Inc., Chicago, Ill., USA), and a p value <0.05 was indicative of a statistically significant difference.
Results

Demographic Data
The size (maximal diameter) of 158 thyroid nodules ranged from 10 to 64 mm (mean ± standard deviation 16.8 ± 8 mm). The RFNA and CNB were performed simultaneously in 146 (92.4%) of the thyroid nodules. The final diagnoses of 91 nodules included 73 (80.2%) benign nodules, including 4 follicular adenomas diagnosed by surgery and 18 (19.8%) malignant nodules. Malignant tumors were found in 13 (22.4%) of 58 NA subcategory nodules (8 conventional papillary carcinomas, 3 follicular variant papillary carcinomas and 2 follicular carcinomas) and in 5 (15.2%) of 33 FOA subcategory nodules (2 conventional papillary carcinomas, 1 follicular variant papillary carcinoma, 1 oncocytic variant papillary carcinoma and 1 follicular carcinoma). The final diagnoses of 73 benign nodules were determined by: (a) the pathological results of surgical resections (n = 11), (b) with benign results of FNA or CNB repeated at least twice (n = 49), or (c) with an initial benign result of FNA or CNB and a decrease of nodule size (n = 13). There were no major complications such as serious hemorrhage in any of the patients and none required hospital admission or intervention. There were no cases of infection or needle track seeding during the follow-up period. Table 1 displays the comparison of diagnostic results between RFNA and CNB in overall AUS/FLUS and each nodule subcategory. The overall nondiagnostic rate of RFNA and CNB was 8.2 and 0% in the nodules, respectively. CNB showed a significantly lower rate of AUS/ FLUS (p = 0.038), higher rates of benign and FN/SFN diagnoses (p = 0.035 and 0.006, respectively), and a margin- 
Comparison of RFNA and CNB Diagnoses in AUS/ FLUS Thyroid Nodules
Comparison of Diagnostic Results between the NA and FOA Subcategory
When the results of RFNA were compared between the NA and FOA subcategories, there was no significant difference in the results of the 6 BSRTC categories (p ≥ 0.185). However, when the CNB results were compared, the FN/SFN rate was significantly higher in the FOA subcategory than that in the NA subcategory (25.9 vs. 12.5%, p = 0.033). There was no significant difference in other BSRTC category results between the NA and FOA subcategories at CNB (p ≥ 0.133).
Management Decision by RFNA and CNB in AUS/ FLUS Thyroid Nodules
CNB demonstrated significantly higher rates of determined management for observation (BSRTC category II) or surgery (BSRTC category IV, V and VI) than RFNA in the overall nodules and the NA subcategory (p < 0.001), and a marginally higher rate of determined management in the FOA subcategory (p = 0.061; table 2 ). CNB demonstrated significantly higher rates of surgery decision than RFNA in both the NA subcategory (20.2 vs. 9.6%, p < 0.001) and the FOA subcategory (20.8 vs. 5.6%, p = 0.007), and a higher rate of observation decision only in the NA subcategory (48.1 vs. 35.6%, p = 0.035). Table 3 depicts the diagnostic values of RFNA and CNB in 91 nodules with final diagnoses. In the overall AUS/FLUS nodules, the sensitivity of CNB for malignancy was higher than that of RFNA with criteria 1 (BSRTC category VI) or criteria 2 (BSRTC category IV/V/VI), but was statistically significant only for criteria 2 (p = 0.021). CNB showed a tendency of higher sensitivity for malignancy than RFNA with criteria 2 in each NA and FOA subcategory, but this was statistically insignificant. The false negative rate of benign diagnosis was found only at RFNA, which was 2% (1/51). The area under the curve of CNB was significantly larger than that of RFNA for the diagnosis of malignancy with criteria 2 in the overall AUS/FLUS nodules by ROC analysis (p = 0.03).
Diagnostic Values of RFNA and CNB for Thyroid Malignancy
The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of RFNA and CNB with criteria 2 (BSRTC category IV/V/VI) for follicular neoplasm among nonneoplastic nodules and follicular neoplasm was 28.6, 100, 100, 90.9 and 91.2% for RFNA, and 71.4, 100, 100, 96.2 and 96.5% for CNB, respectively. The sensitivity of CNB for follicular neoplasm was higher than that of RFNA, but was statistically insignificant (p = 0.375).
In 91 nodules with final diagnoses, the malignancy rate of repeated AUS/FLUS result by RFNA was similar or slightly higher than that by CNB overall in the nodules (29.2 vs. 20%, respectively) and at each subcategory (NA 26.7 vs. 25%, and FOA 33.3 vs. 14.3%, respectively).
Discussion
Our data demonstrates that the rate of overall management decision determined by CNB was significantly higher than that by RFNA in both the NA and FOA subcategories. The rate of surgery decision was significantly higher at CNB than that at RFNA in both the NA and FOA subcategories and the rate of observation decision was marginally higher only in the NA subcategory. Furthermore, CNB demonstrated a better diagnostic performance than RFNA overall in the AUS/FLUS nodules, and a higher sensitivity for malignancy with the criteria 2 (BSRTC category IV/V/VI) in both the NA and FOA subcategories, thus maintaining the high specificity compared with RFNA.
This study reproduces the result of a previous report [17] that CNB can reduce the inconclusive diagnostic results (nondiagnostic and AUS/FLUS) and has a higher sensitivity for thyroid malignancy than RFNA overall in AUS/FLUS nodules, and the present study additionally demonstrates a higher efficacy of CNB for management decisions at each subcategory of AUS/FLUS nodules.
The overall lower rate of repeated AUS/FLUS result at CNB may be explained mainly by two factors -sufficient biopsy tissue sample and better information of nodule architecture at CNB ( fig. 2-4) . First, the cytology diagnosis of AUS/FLUS is strongly related to a paucicellular FNA specimen that manifests as scenarios of NA, architectural atypia and oncocytic pattern in paucicellular aspirates [3] , and, therefore, this causative factor for AUS/FLUS diagnosis at FNA may be overcome by a large tissue sample of CNB. Second, CNB can provide more information of nodule architecture by tissue sampling, including the nodule, nodule margin (information of capsule) and adjacent normal glandular tissue [19] . This factor may also be a major cause for a higher rate of FN/SFN diagnosis at CNB in both the NA and FOA subcategories compared with RFNA.
However, the data of subcategory analysis at CNB show different results between the NA and FOA subcategories. First, in contrast to the NA subcategory, there was no significant difference in the rate of malignant and benign diagnoses between RFNA and CNB in the FOA subcategory. Second, CNB showed a higher rate of FN/ SFN diagnosis in the FOA subcategory than that in the NA subcategory. These differences between the NA and FOA subcategories seem closely related to the difference of histopathology because the FOA subcategory included mostly follicular lesions showing predominant microfollicle formation and rarely showing NA for papillary thyroid carcinoma. Our results also suggest that CNB is superior to RFNA in the diagnosis of follicular neoplasm in both the NA and FOA subcategories, which is supported by recent reports [25, 26] that CNB is more sensitive and predictive of follicular neoplasm, and which could be explained by an advantage of CNB in providing better information of nodule architecture.
Our data demonstrated that CNB was more useful for management decisions relating to AUS/FLUS nodules than RFNA due to fewer inconclusive results at each NA and FO subcategory as well as overall AUS/FLUS nodules. Although management decisions of surgery or observation could be made more effectively at CNB compared with RFNA in the NA subcategory, only the management decision of surgery could be made more effectively at CNB in the FOA subcategory. This might be partly caused by a difficulty in categorizing a cellular hyperplastic nodule without a capsule in CNB specimens as benign, which was usually categorized as AUS/FLUS in the present study due to a concern of follicular variant papillary thyroid carcinoma or follicular carcinoma. Further investigations are required to establish the standardized criteria for a histology diagnosis in CNB. In our study, the sensitivity of CNB for malignancy with criteria 2 was 30.8% higher than RFNA in the NA subcategory and 60% higher in the FOA subcategory ( table 3 ) . The results of a higher rate of management decision and higher diagnostic accuracy for malignancy at CNB suggest that CNB may reduce the rate of unnecessary diagnostic surgery due to repeated inconclusive results, and has the potential to be a first-line alternative diagnostic method in AUS/FLUS nodules. However, the optimal strategy for management decisions in the nodules showing repeated AUS/FLUS results at CNB remains to be investigated. In our study, the malignancy risk of repeated AUS/FLUS results at CNB was not substantially higher than the malignancy risk of the initial AUS/FLUS results, which suggests that a decision for surgery needs to be made conservatively after estimating the overall malignancy risk with clinical features, US findings [20, 27] and other ancillary tests such as immunohistochemical studies [19, 28, 29] .
We tried to obtain qualified cytology or histology specimens at each FNA or CNB procedure. The nondiagnostic rate of FNA was less than 10%, which supports the adequacy of FNA results in our study. Although the procedural safety of CNB is still a concern for some, previous studies [24, 30, 31] suggest that CNB is safe and tolerable, and the procedural technique of CNB is similarly feasible compared with FNA for a radiologist or thyroidologist experienced in thyroid intervention. This study has several limitations. First, there was an inevitable patient selection bias due to the retrospective nature of the study. Second, the results of CNB may have been influenced by the technique and experience of the operator and pathologist.
In conclusion, CNB may be more useful for guiding management decisions than RFNA in both the NA and FOA subcategories, and has a potential to be a first-line alternative diagnostic tool in initially diagnosed AUS/ FLUS nodules.
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